Xiaochun Wan | Tumor Immunology | Best Researcher Award

Posted on by sciencefather

Prof. Xiaochun Wan | Tumor Immunology | Best Researcher Award

Dr. Xiaochun Wan is a distinguished immunologist and cancer researcher at the Chinese Academy of Sciences, serving as the Deputy Director of the Institute of Biomedicine and Biotechnology. With a Ph.D. in Immunology from the University of Montreal and postdoctoral training at the University of Pennsylvania, he has pioneered advancements in immune cell therapy, CAR-T technology, and monoclonal antibodies. His work has led to over 40 high-impact publications and 150+ patents, securing nearly RMB 200 million in research funding. Dr. Wan’s groundbreaking therapies have successfully treated 100+ cancer patients, positioning him as a leader in precision oncology and immunotherapy innovation.

Prof. Xiaochun Wan | ShenZhen Institute of Advance Technologies | China

Profile

SCOPUS ID

ORCID ID

🎓 Education

  • Dr. Xiaochun Wan earned his Ph.D. in Immunology from the University of Montreal in 2003. Following his doctoral studies, he pursued postdoctoral research at the University of Pennsylvania, focusing on advanced immunological therapies.

💼 Experience

  • Dr. Wan is a distinguished researcher at the Chinese Academy of Sciences and serves as the deputy director at the Institute of Biomedicine and Biotechnology. He is also the executive director of the Center for Protein and Cell-based Drugs at the Shenzhen Institutes of Advanced Technology. Before his current roles, he worked as a senior researcher at Merck, where he contributed to the development of monoclonal antibody-based drugs.

🔥 Awards and Achievements

  • Dr. Wan has received numerous prestigious awards, including the Canadian Institutes of Health Research (CIHR) Excellent Researcher Award and the International Federation of Clinical Immunology Conference Paper Award, recognizing his outstanding contributions to the field of immunology.

🛠️ Skills and Certifications

  • Dr. Wan specializes in immune cell therapy and monoclonal antibody research, with extensive expertise in drug development, clinical applications, and biotechnology innovation. His proficiency in translational medicine has significantly advanced therapeutic strategies for cancer treatment.

🔬 Research Focus

  • Dr. Wan’s research primarily focuses on immune cell therapy, particularly CAR-T cell technology, and monoclonal antibody development. He has published over 40 papers in leading journals such as JEM, Cancer Research, and the Journal of Immunology. With more than 150 patents to his name, he has secured substantial research funding from NSFC, Guangdong Province, and Shenzhen, totaling nearly RMB 200 million. In 2019, his team successfully submitted two national 1.1 major new drug IND applications. His CAR-T cell therapy has treated over 100 cancer patients, achieving internationally advanced clinical efficacy.

Conclusion

  • Dr. Wan’s dedication to advancing tumor immunology has led to life-saving therapies and transformative scientific discoveries. His combination of innovative research, real-world impact, and leadership in immunotherapy development positions him as an ideal recipient of this prestigious award. His work continues to shape the future of cancer treatment and immuno-oncology research globally.

📄Publications

  • Multifaceted roles of DLG3/SAP102 in neurophysiology, neurological disorders and tumorigenesis
    Authors: K.I. Gidado, F.O. Adeshakin, L. Rabiu, G. Zhang, X. Wan
    Journal: Neuroscience, 2025

  • CRISPR knock-in of a chimeric antigen receptor into GAPDH 3’UTR locus generates potent B7H3-specific NK-92MI cells
    Authors: L. Dai, P. Zhang, X. Niu, G. Zhang, X. Wan
    Journal: Cancer Gene Therapy, 2025

  • Blockade of TIPE2-Mediated Ferroptosis of Myeloid-Derived Suppressor Cells Achieves the Full Potential of Combinatory Ferroptosis and Anti-PD-L1 Cancer Immunotherapy
    Authors: H.K. Tariq, Z. Liang, L. Rabiu, X. Wan, D. Yan
    Journal: Cells, 2025

  • MDSC: a new potential breakthrough in CAR-T therapy for solid tumors
    Authors: N.M.F. Abdalsalam, A. Ibrahim, M.A. Saliu, X. Wan, D. Yan
    Journal: Cell Communication and Signaling, 2024

  • Immunological dynamics in MASH: from landscape analysis to therapeutic intervention
    Authors: L. Rabiu, P. Zhang, L.O. Afolabi, G. Zhang, X. Wan
    Journal: Journal of Gastroenterology, 2024

Feng Xu | Immunology | Best Researcher Award

Posted on by sciencefather

Dr. Feng Xu | Immunology |Best Researcher Award

Recognition in Research:
  •  Dr. Xu’s research into the biochemical pathways involved in ulcerative colitis treatment, such as his work on activating PPAR-γ signaling, demonstrates his potential for groundbreaking discoveries in TCM’s role in gastrointestinal diseases.
 Dr. Feng Xu, Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, China

Profile

Scopus

🏛️Early Academic Pursuits

  • Dr. Feng Xu graduated from Nanjing University of Chinese Medicine, earning a Ph.D. in Traditional Chinese Medicine (TCM) Internal Medicine. His passion for understanding and addressing chronic gastrointestinal conditions, particularly ulcerative colitis, guided his academic journey. Feng Xu developed a keen interest in the intersection of traditional Chinese medicine and modern therapeutic approaches, aiming to bridge the gap between ancient practices and contemporary medical needs.

👨‍🔬 PROFESSIONAL ENDEAVORS

  • Currently, Dr. Xu works at the Third Clinical Medical College of Zhejiang Chinese Medical University, applying his expertise in TCM to real-world clinical settings. His ongoing research into the treatment of ulcerative colitis with traditional Chinese medicine has established him as a key figure in this specialized field. Alongside his work in academia, Dr. Xu continues to contribute to the medical community through active participation in research and innovative treatment methods.

🏆 CONTRIBUTIONS AND RESEARCH FOCUS

  • Dr. Xu’s work focuses on the Traditional Chinese Medicine treatment of ulcerative colitis, with a particular emphasis on herbal remedies. His research into Qin-Yu-Qing-Chang decoction has revealed significant findings, showing that it reshapes colonic metabolism by activating PPAR-γ signaling, effectively targeting facultative anaerobes in colitis treatment. His studies have contributed to a better understanding of colitis and its relationship with metabolic processes, offering promising alternative therapies for patients.

📊 IMPACT AND INFLUENCE

  • Dr. Feng Xu has gained recognition for his pioneering studies in ulcerative colitis, influencing the approach to treatment through TCM. His 2022 cross-sectional study on the prevalence of fatigue in ulcerative colitis patients in China highlighted critical aspects of patient well-being, providing valuable data for both medical practitioners and researchers. His innovative work on herbal decoctions for colitis management has also sparked interest in integrating natural medicine with conventional treatment methods.

🏅ACADEMIC CITES

  • Dr. Xu has published significant research papers, such as:

    1. “Prevalence and factors associated with fatigue in patients with ulcerative colitis in China: a cross-sectional study” (BMC Gastroenterol, 2022).
    2. “Qin-Yu-Qing-Chang decoction reshapes colonic metabolism by activating PPAR-γ signaling to inhibit facultative anaerobes against DSS-induced colitis” (Chin Med, 2024).

    These publications have contributed to the growing body of knowledge on TCM’s role in gastrointestinal health, garnering recognition within academic circles.

🚀 LEGACY AND FUTURE CONTRIBUTIONS

  • With a promising research portfolio, Dr. Feng Xu is poised to continue his impactful work in the field of TCM and ulcerative colitis treatment. His contributions to alternative medicine will likely pave the way for further exploration of traditional Chinese remedies in modern healthcare, improving patient outcomes and enhancing the understanding of chronic gastrointestinal diseases.

📰PUBLICATIONS

    •  Qin-Yu-Qing-Chang decoction reshapes colonic metabolism by activating PPAR-γ signaling to inhibit facultative anaerobes against DSS-induced colitis
      Author(s): Xu, F., Hu, J., Li, Y., Zhu, L., Shen, H.
      Journal: Chinese Medicine (United Kingdom), 2024, 19(1), 130
    •  A network pharmacology approach and experimental validation to investigate the anticancer mechanism of Qi-Qin-Hu-Chang formula against colitis-associated colorectal cancer through induction of apoptosis via JNK/p38 MAPK signaling pathway
      Author(s): Wu, Y., Fang, Y., Li, Y., Zhu, L., Shen, H.
      Journal: Journal of Ethnopharmacology, 2024, 319, 117323
    • Therapeutic Effects of Qingchang Tongluo Decoction on Intestinal Fibrosis in Crohn’s Disease: Network Pharmacology, Molecular Docking and Experiment Validation
      Author(s): Li, Y., Hu, J., Au, R., Zhu, L., Shen, H.
      Journal: Drug Design, Development and Therapy, 2024, 18, pp. 3269–3293
    • Integrated Network Pharmacology, Molecular Docking and Animal Experiment to Explore the Efficacy and Potential Mechanism of Baiyu Decoction Against Ulcerative Colitis by Enema
      Author(s): Cui, Y., Hu, J., Li, Y., Zhu, L., Shen, H.
      Journal: Drug Design, Development and Therapy, 2023, 17, pp. 3453–3472
    •  Association of serum lipids with inflammatory bowel disease: a systematic review and meta-analysis
      Author(s): Chen, H., Li, W., Hu, J., Zhu, L., Shen, H.
      Journal: Frontiers in Medicine, 2023, 10, 1198988